Acute myeloid leukemia is the most common form of acute leukemia in adults. Its incidence in the major pharmaceutical markets under study is increasing, largely as a result of the aging population.
A range of therapies are used to treat AML; however, the market is dominated by the use of agents that induce DNA damage. As drug treatments and clinical trial designs continue to evolve, novel agents with new mechanisms of action are set to enter this market.
- The AML population will continue to grow during our forecast period due to population aging as well as population growth. What is the size of the U.S. and EU5 (France, Germany, Italy, Spain, and U.K.) AML populations, and how will they change over the forecast period?
- Several drug classes are in late-stage development for AML, including kinase inhibitors, hypomethylating agents, nucleoside analogues, and anti-KIR agents. What do experts think about the prospects of emerging therapies? For which agents, if any, do we forecast a launch in AML, and how will they affect the AML landscape?
- A high level of unmet need exists in AML for several key populations. What are the key unmet needs in AML treatment according to interviewed experts? Will any of these unmet needs be addressed during the next ten years?
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Three key opinion leaders from the United States and five from Europe with expertise in AML treatment were interviewed for this report.
Epidemiology: Diagnosed incident cases of AML (excluding APL) and APL in the United States and EU5.
Population segments in market forecast: First-line AML (excluding APL), relapsed/refractory AML (excluding APL), first-line APL, relapsed/refractory APL.
Emerging therapies: Phase I/II: 4 drugs; Phase III: 8 drugs.